Abstract

In initial human trials, synthetic vaccines have induced humoral immunity sufficient to prevent clinical infection in some cases and delay it in others. Progress in induction of cellular immunity is also noteworthy with identification of determinants recognized by T cells. Antigenic variation and consequent blunting of immunogenicity may not be as troublesome as feared.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.